Kairos Pharma, Ltd.
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to dep… Read more
Kairos Pharma, Ltd. (KAPA) - Net Assets
Latest net assets as of September 2025: $7.66 Million USD
Based on the latest financial reports, Kairos Pharma, Ltd. (KAPA) has net assets worth $7.66 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.07 Million) and total liabilities ($402.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.66 Million |
| % of Total Assets | 95.02% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Kairos Pharma, Ltd. - Net Assets Trend (2020–2024)
This chart illustrates how Kairos Pharma, Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Kairos Pharma, Ltd. (2020–2024)
The table below shows the annual net assets of Kairos Pharma, Ltd. from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $4.78 Million | +329.84% |
| 2023-12-31 | $-2.08 Million | -76.25% |
| 2022-12-31 | $-1.18 Million | -1.03% |
| 2021-12-31 | $-1.17 Million | -240.39% |
| 2020-12-31 | $-342.84K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kairos Pharma, Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 761016200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $14.00K | 0.29% |
| Other Components | $13.58 Million | 284.28% |
| Total Equity | $4.78 Million | 100.00% |
Kairos Pharma, Ltd. Competitors by Market Cap
The table below lists competitors of Kairos Pharma, Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Y/KNOT S.A.
AT:YKNOT
|
$7.38 Million |
|
Corus Entertainment Inc
PINK:CJREF
|
$7.39 Million |
|
M2A0
F:M2A0
|
$7.39 Million |
|
Turbo Energy, S.A. American Depositary Shares
NASDAQ:TURB
|
$7.39 Million |
|
T T Limited
NSE:TTL
|
$7.38 Million |
|
Nuvotec
KQ:060260
|
$7.38 Million |
|
Induct AS
OL:INDCT
|
$7.38 Million |
|
Macromill Embrain Co. Ltd
KQ:169330
|
$7.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kairos Pharma, Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -2,078,000 to 4,776,000, a change of 6,854,000.
- Net loss of 2,603,000 reduced equity.
- New share issuances of 5,524,000 increased equity.
- Other factors increased equity by 3,933,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.60 Million | -54.5% |
| Share Issuances | $5.52 Million | +115.66% |
| Other Changes | $3.93 Million | +82.35% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Kairos Pharma, Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.48x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-0.03 | $0.62 | x |
| 2021-12-31 | $-0.09 | $0.62 | x |
| 2022-12-31 | $-0.12 | $0.62 | x |
| 2023-12-31 | $-0.20 | $0.62 | x |
| 2024-12-31 | $0.42 | $0.62 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kairos Pharma, Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -54.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.30x
- Recent ROE (-54.50%) is below the historical average (-10.90%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.02 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.03 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-932.10K |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.60 Million |
| 2024 | -54.50% | 0.00% | 0.00x | 1.30x | $-3.08 Million |
Industry Comparison
This section compares Kairos Pharma, Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kairos Pharma, Ltd. (KAPA) | $7.66 Million | 0.00% | 0.05x | $7.38 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |